Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report

• Published in: Annals of medicine and surgery 2023-02, Vol.85 (2), p.257-260
• Main Authors: Gurung, Shekhar, Karki, Saurab, Khadka, Manoj, Bhatta, Bhuwan, Adhikari, Ayush, Shrestha, Amar N
• Format: Article
• Language: English
• Subjects: Case Reports
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000000198

Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.